Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | EBP | Q15125 | 3/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176092 | 0.88 | DRD2 (0.35) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176083 | 0.86 | DRD2 (0.35) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176084 | 0.85 | DRD2 (0.35) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176086 | 0.85 | DRD2 (0.35) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176072 | 0.85 | DRD2 (0.35) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176085 | 0.84 | DRD2 (0.34) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176087 | 0.83 | DRD2 (0.33) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176093 | 0.82 | EBP (0.33) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176091 | 0.82 | CTSS (0.33) | DRD2DRD4OPRM1DRD3EBP | |
| SCHEMBL20176074 | 0.81 | DRD2 (0.32) | DRD2DRD4OPRM1DRD3EBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141964-A1 | FUNCTIONALIZED CYANOSILANE AND SYNTHESIS METHOD AND USE THEREOF | EAST CHINA NORMAL UNIVERSITY (CN) | 2018-05-24 | — | — | US | disclosed |
| US-6677461-B2 | CYANOSILATION CATALYST | JAPAN AS REPRESENTED BY PRESIDENT OF THE UNIVERSITY OF TOKYO (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030119659-A1 | Ligands and asymmetric catalysts made by using the same | JAPAN AS REPRESENTED BY PRESIDENT OF THE UNIVERSITY OF TOKYO (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119659-A1 | Ligands and asymmetric catalysts made by using the same | AP2A1, AP3D1, AP3M1 | DRD2 938/4885DRD4 732/4885OPRM1 52/4885 |
| US-20180141964-A1 | FUNCTIONALIZED CYANOSILANE AND SYNTHESIS METHOD AND USE THEREOF | NCLN, PNN, MB | DRD2 2601/4885DRD4 2341/4885OPRM1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.